- Home
- PRQR vs TLSA Comparison
PRQR vs TLSA Comparison
Compare PRQR & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- TLSA
- Stock Information
- Founded
- PRQR 2012
- TLSA 2013
- Country
- PRQR Netherlands
- TLSA United Kingdom
- Employees
- PRQR N/A
- TLSA N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- PRQR Health Care
- TLSA Health Care
- Exchange
- PRQR Nasdaq
- TLSA Nasdaq
- Market Cap
- PRQR 232.8M
- TLSA 187.0M
- IPO Year
- PRQR 2014
- TLSA 2000
- Fundamental
- Price
- PRQR $2.15
- TLSA $1.73
- Analyst Decision
- PRQR Strong Buy
- TLSA
- Analyst Count
- PRQR 8
- TLSA 0
- Target Price
- PRQR $8.88
- TLSA N/A
- AVG Volume (30 Days)
- PRQR 368.1K
- TLSA 325.5K
- Earning Date
- PRQR 11-06-2025
- TLSA 05-06-2025
- Dividend Yield
- PRQR N/A
- TLSA N/A
- EPS Growth
- PRQR N/A
- TLSA N/A
- EPS
- PRQR N/A
- TLSA N/A
- Revenue
- PRQR $20,129,184.00
- TLSA N/A
- Revenue This Year
- PRQR N/A
- TLSA N/A
- Revenue Next Year
- PRQR N/A
- TLSA N/A
- P/E Ratio
- PRQR N/A
- TLSA N/A
- Revenue Growth
- PRQR 8.65
- TLSA N/A
- 52 Week Low
- PRQR $1.07
- TLSA $0.63
- 52 Week High
- PRQR $4.62
- TLSA $2.60
- Technical
- Relative Strength Index (RSI)
- PRQR 49.40
- TLSA 47.47
- Support Level
- PRQR $1.91
- TLSA $1.63
- Resistance Level
- PRQR $2.50
- TLSA $1.88
- Average True Range (ATR)
- PRQR 0.16
- TLSA 0.16
- MACD
- PRQR -0.03
- TLSA -0.00
- Stochastic Oscillator
- PRQR 44.07
- TLSA 60.26
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.